Researchers at University Hospital Southampton, with the Medicines Evaluation Unit (MEU) in Manchester, ran the world’s first clinical trial of a fridge-free tetanus-diphtheria vaccine, which uses UK-developed technology to remain stable at room temperature. The study, published in The Lancet’s eClinicalMedicine, found the vaccine to be safe, well-tolerated, and as effective as current refrigerated vaccines. "Our study suggests that this vaccine can remain safe and effective without refrigeration. READ MORE: Cancer charity funds new equipment to improve treatment at Southampton hospitalResearchers have run the world's first clinical trial of a fridge-free tetanus-diptheria vaccine. The phase one trial, delivered through the NIHR Biomedical Research Centre in Southampton, enrolled 60 healthy adults.